Seth Klarman Nuvation Bio Inc. Transaction History

Baupost Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$1.68 - $2.5 $9.42 Million - $14 Million	-5,610,000 Reduced 53.85%	4,808,194 $9.23 Million
Q2 2022 Aug 12, 2022	SELL	$3.24 - $5.85 $81,972 - $148,005	-25,300 Reduced 0.24%	10,418,194 $33.8 Million
Q1 2022 May 13, 2022	BUY	$4.6 - $8.83 $8.37 Million - $16.1 Million	1,820,473 Added 21.11%	10,443,494 $54.9 Million
Q1 2021 May 14, 2021	BUY	$9.0 - $14.57 $77.6 Million - $126 Million	8,623,021 New	8,623,021 $82.4 Million

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Baupost Group LLC, based on Form 13F filings with the SEC.

Stay updated on Baupost Group LLC and Seth Klarman with notifications on news.